



# **Prevantics®**

Prevent the spread of HAIs with the first and **ONLY** 3.15% CHG/70% IPA formulation with up to 7 days of continued antimicrobial activity.\*

\*Swabstick and Maxi Swabstick only

 **PDI®**  
BE THE DIFFERENCE™

# THE CHALLENGE

There were an estimated 722,000 HAIs in U.S. hospitals in 2011, resulting in an estimated 75,000 patient deaths.<sup>1</sup> HAIs affect patients, their families and the people who care for them. They also have an impact on hospital costs and quality. The CDC estimated that CLABSI cost facilities \$16,550 per infection.<sup>2</sup>

# THE SOLUTION

Prevantics® products, designed with 3.15% Chlorhexidine Gluconate (w/v) and 70% Isopropyl Alcohol (v/v) formulation, help prevent the spread of infections and help improve patient outcomes.



## Designed for Convenience

Prevantics® products are a convenient delivery system that has no sharp glass to break or activation required.

### Prevantics® Applicators

- No glass to break
- Pre-activated
- No waiting
- Easy to open, easy to use
- Pre-moistened
- Swab: Intuitive prep-pad design
- Swabsticks: Unique 2-sided applicator for interdigital areas and skin folds



Prevantics® 1.0 mL Swab



Prevantics® 1.6 mL Swabstick



Prevantics® 5.1 mL Maxi Swabstick

<sup>1</sup>CDC HAI Prevalence Survey. Magill SS, Edwards JR, Bamberg W, et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N Engl J Med 2014;370:1198-208.

<sup>2</sup>CDC Vital Signs: Central Line-Associated Blood Stream Infections - United States, 2001, 2008 and 2009. MMWR Weekly, March 4, 2011, 60(08);243-248. [www.cdc.gov/mmwr/preview/mmwrhtml/mm6008a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6008a4.htm)

**Prevantics® products are the first and only FDA approved 3.15% Chlorhexidine Gluconate (w/v) and 70% Isopropyl Alcohol (v/v) solution.**

## The Prevantics® Difference


The efficacy of Prevantics® products closely correlate with dressing change protocols at many facilities.



## Clinical Case Study

A leading facility who has implemented Prevantics® products to improve patient outcomes.

**The Rush-Copley Medical Center Study resulted in a CLABSI reduction of 59% in year 1 and a 100% reduction by year 4.**












\*Swabstick and Maxi Swabstick only

<sup>3</sup>Matocha et al. A Process Improvement Approach to the Elimination of Central Line Associated Bloodstream Infections. Rush-Copley Medical Center, Aurora, IL. October 2011.

<sup>4</sup>Marlowe, Lauren; Mistry, Rakesh D. et al. Blood Culture Contamination Rates after Skin Antisepsis with Chlorhexidine Gluconate versus Povidone-Iodine in a Pediatric Emergency Department. Infection Control and Hospital Epidemiology. February 2010, vol. 31, no. 2.

**Prevantics®** products are available in a variety of convenient, ready-to-use applicators: Swab, Swabstick and Maxi Swabstick.

## PRODUCT BENEFITS

<b>Saves Time</b>	<ul style="list-style-type: none"> <li>• Pre-moistened. No waiting for activation</li> <li>• Unique 2-sided applicators*</li> <li>• No glass</li> <li>• Easy to open packaging</li> </ul>
<b>Saves Money</b>	<ul style="list-style-type: none"> <li>• Effective skin antisepsis will help improve patient outcomes and reduce healthcare costs</li> </ul>
<b>Improves Outcomes</b>	<ul style="list-style-type: none"> <li>• Up to 7 days of continued antimicrobial activity*</li> <li>• Clinical compendium with summary of independent studies</li> <li>• 14 independent clinical studies demonstrating clinical efficacy with Prevantics® products</li> </ul>
<b>Meets Evidence-Based Clinical Guidelines</b>	<p>• Prevantics® products meet the skin antisepsis guidelines from:</p> <div>          </div>

## ORDER INFORMATION

Individual Boxes	Reorder No.	Swabs/Swabsticks Per Box	Boxes Per Case	Treatment Area Covered
<b>Prevantics® Swab 1.0 mL</b> Preinjection Indication	B10800	100	10	2.5" x 2.5" in <sup>2</sup> (6.25 in <sup>2</sup> / 6 x 6 cm)
<b>Prevantics® Swabstick 1.6 mL</b> Preinjection and Preoperative Indications	S40750	50	10	Dry Site: 4" x 4" in <sup>2</sup> (16 in <sup>2</sup> / 10 x 10 cm) Moist Site: 3" x 5" in <sup>2</sup> (15 in <sup>2</sup> / 7.5 x 12.5 cm)
<b>Prevantics® Maxi Swabstick 5.1 mL</b> Preinjection and Preoperative Indications	S41950	30	10	Dry Site: 7" x 7" in <sup>2</sup> (49 in <sup>2</sup> / 18 x 18 cm) Moist Site: 3" x 7.5" in <sup>2</sup> (22.5 in <sup>2</sup> / 7.5 x 19 cm)

\*Swabstick and Maxi Swabstick only

### PDI

Two Nice-Pak Park  
Orangeburg, New York 10962  
Customer Service: 800.999.6423  
pdihc.com

©2014 Professional Disposables International, Inc. All rights reserved.

